News
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
16h
24/7 Wall St. on MSNHims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Palantir Technologies raises its full-year outlook but the stock falls, Ford suspends guidance because of uncertainty over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results